Lpathomab Biosimilar – Anti-LPA mAb – Research Grade from ProteoGenix; catalogue PX-TA2293; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Lpathomab Biosimilar, also known as Anti-LPA mAb, is a monoclonal antibody designed to target and inhibit the activity of lysophosphatidic acid (LPA) in the body. LPA is a bioactive lipid molecule that has been implicated in various diseases and disorders, making it a promising therapeutic target. Lpathomab Biosimilar is a research grade version of the original Lpathomab, developed for use in laboratory settings for scientific research purposes.
Lpathomab Biosimilar is a monoclonal antibody, meaning it is a type of protein produced by immune cells that specifically binds to a particular target molecule. It is a fully humanized antibody, meaning it is derived from human cells and has a structure that closely resembles natural human antibodies. This makes it less likely to cause an immune response in the body, making it a safer and more effective therapeutic option.
The antibody has a Y-shaped structure, with two identical arms that each contain a heavy chain and a light chain. These chains are made up of amino acids and are responsible for the antibody’s binding specificity. The heavy chain is responsible for the antibody’s overall structure and stability, while the light chain is responsible for binding to the target molecule, in this case, LPA.
The main activity of Lpathomab Biosimilar is to bind to LPA and prevent it from exerting its effects on cells in the body. LPA is a signaling molecule that binds to specific receptors on the surface of cells, triggering a cascade of events that can lead to various physiological responses. By binding to LPA, Lpathomab Biosimilar blocks its interaction with these receptors, effectively inhibiting its activity.
In addition to this, Lpathomab Biosimilar also has the potential to neutralize the effects of LPA that are already present in the body. This is because the antibody has a high binding affinity for LPA, meaning it can outcompete LPA for binding to its receptors. This can help to reduce the overall levels of LPA in the body and alleviate the symptoms of LPA-related diseases.
Lpathomab Biosimilar has potential applications in various fields of scientific research, particularly in the study of LPA-related diseases. LPA has been implicated in a range of conditions, including cancer, fibrosis, and neuropathic pain, making it a promising therapeutic target for these diseases. By using Lpathomab Biosimilar in laboratory settings, researchers can better understand the role of LPA in these diseases and potentially develop new treatments that target LPA.
In addition to this, Lpathomab Biosimilar can also be used in preclinical studies to evaluate its potential as a therapeutic agent. This involves testing the antibody in animal models of LPA-related diseases to assess its safety, efficacy, and potential side effects. This can help to determine the potential of Lpathomab Biosimilar as a future treatment option for these diseases.
Lpathomab Biosimilar, also known as Anti-LPA mAb, is a research grade monoclonal antibody designed to target and inhibit the activity of LPA. Its fully humanized structure and high binding affinity make it a promising therapeutic option for LPA-related diseases. Its potential applications in scientific research and preclinical studies make it a valuable tool in the study and development of treatments for these diseases. Further research and development of Lpathomab Biosimilar may lead to its potential use as a therapeutic agent in the future.
ProteoGenix catalogue number PX-TA2293. For research use only.
Target: LPA; Clonality: Monoclonal Antibody; Applications: Block.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Block |
|---|---|---|---|---|---|---|---|---|---|
| LPA |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
